At diagnosis, 5–10% of high-risk prostate adenocarcinomas have synchronous nodal metastases on CT.1 The incidence is probably much higher, as nodal metastases detection increases to 30% using prostate-specific membrane antigen positron-emission tomography (PSMA-PET).2,3 The management of non-metastatic prostate adenocarcinoma with regional nodal metastases (cN1 patients) is controversial. This evidence concerns the gene FOLH1 and prostate adenocarcinoma.